TapewireFind a company

person · Reporting owner

Kumar Rakhi

Disclosed activity across 3 companies

Tapewire entity
36254
SEC CIK
0001856296

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Amanat Acquisition Corp.AMAN · Entity 6741DirectorMay 18, 2026May 19, 2026
NeuroPace IncNPCE · Entity 5459DirectorJune 19, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amanat Acquisition Corp.

Report date May 18, 2026 · Filed May 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible securityIndirectSee footnoteNot disclosed Reported balance Holding disclosure · report date 2026-05-18 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.

F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.

F2: For her services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.

NeuroPace Inc

Report date June 19, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,039 Reported balance After 2026-06-19 transaction · row 1
1 source row

Row 1 · 2026-06-19 · Grant · Acquired 989 · Balance 23,039

F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Roivant Sciences Ltd.

Report date February 20, 2025 · Filed February 25, 2025

Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect162,306 Reported balance After 2025-02-20 transaction · row 1
1 source row

Row 1 · 2025-02-20 · Tax withholding · Disposed 958 · Balance 162,306

F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 08, 2023 Filed Sep 13, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 99,350 $6.48 $643,788.00
Disclosure

SEC source: 0001140361-23-043730 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 05, 2023 Filed Sep 8, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 1,724 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001140361-23-043270 · form4.xml · derivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,350

Underlying: Common Shares · 1,724 shares

Expires 2027-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested.

Read SEC document
September 05, 2023 Filed Sep 8, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 1,724 $12.00 $20,688.00
Disclosure

SEC source: 0001140361-23-043270 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,950

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
September 05, 2023 Filed Sep 8, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 1,724 $6.48 $11,171.52
Disclosure

SEC source: 0001140361-23-043270 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,674

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 22, 2023 Filed Aug 25, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,378 $10.83 $14,923.74
Disclosure

SEC source: 0001140361-23-041199 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,950

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
August 03, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 3,681 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · derivative · entry 6

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,074

Underlying: Common Shares · 3,681 shares

Expires 2027-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares. The award of stock options is fully vested.

Read SEC document
August 03, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 3,681 $12.00 $44,172.00
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 4

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,328

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
August 03, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 3,681 $6.48 $23,852.88
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 01, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 336 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · derivative · entry 5

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,755

Underlying: Common Shares · 336 shares

Expires 2027-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares. The award of stock options is fully vested.

Read SEC document
August 01, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 336 $12.00 $4,032.00
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,328

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
August 01, 2023 Filed Aug 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 336 $6.48 $2,177.28
Disclosure

SEC source: 0001140361-23-037941 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 24, 2023 Filed Jul 27, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,393 $10.99 $15,309.07
Disclosure

SEC source: 0001140361-23-036309 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,328

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 100 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · derivative · entry 6

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,091

Underlying: Common Shares · 100 shares

Expires 2027-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 100 $12.00 $1,200.00
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 4

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,128

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 100 $6.48 $648.00
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
July 14, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 535 $0.00 Strike: $6.48 $0.00
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · derivative · entry 5

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,191

Underlying: Common Shares · 535 shares

Expires 2027-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of May 20, 2017. The award of stock options is fully vested.

Read SEC document
July 14, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 535 $12.00 $6,420.00
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,128

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
July 14, 2023 Filed Jul 19, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 535 $6.48 $3,466.80
Disclosure

SEC source: 0001140361-23-035096 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,663

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
June 30, 2023 Filed Jun 24, 2025 20:30 UTC NeuroPace Inc NPCE · Entity 5459 GrantCommon Stock 3,340 $4.49 $14,996.60
Disclosure

SEC source: 0001415889-25-018089 · form4-06242025_040603.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,340

F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.

Read SEC document
June 22, 2023 Filed Jun 27, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,357 $10.01 $13,583.57
Disclosure

SEC source: 0001140361-23-031546 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,225

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 43,893 $0.00 Strike: $5.12 $0.00
Disclosure

SEC source: 0001140361-23-029728 · form4.xml · derivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 43,893 shares

Expires 2025-12-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 30, 2015. The award of stock options is fully vested.

Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 43,893 $9.93 $435,857.49
Disclosure

SEC source: 0001140361-23-029728 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,582

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
June 09, 2023 Filed Jun 14, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 43,893 $5.12 $224,732.16
Disclosure

SEC source: 0001140361-23-029728 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 07, 2023 Filed Jun 14, 2023 20:56 UTC NeuroPace Inc NPCE · Entity 5459 GrantStock Option (Rt to Buy) · Derivative 27,380 $0.00 Strike: $4.20 $0.00
Disclosure

SEC source: 0001209191-23-037074 · doc4.xml · derivative · entry 1

Kumar Rakhi · CIK 0001856296 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,380

Underlying: Common Stock · 27,380 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable.

Read SEC document
May 23, 2023 Filed May 26, 2023 01:31 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,557 $9.58 $14,916.06
Disclosure

SEC source: 0001140361-23-026782 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,582

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
May 02, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 15,517 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · derivative · entry 6

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Shares · 15,517 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
May 02, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 15,517 $8.42 $130,653.14
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 4

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,139

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
May 02, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 15,517 $3.85 $59,740.45
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,656

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 62,219 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · derivative · entry 5

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 765,517

Underlying: Common Shares · 62,219 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
May 01, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 62,219 $8.58 $533,839.02
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,139

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
May 01, 2023 Filed May 4, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 62,219 $3.85 $239,543.15
Disclosure

SEC source: 0001140361-23-022809 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 262,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 28, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 71,989 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · derivative · entry 13

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 827,736

Underlying: Common Shares · 71,989 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
April 28, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 71,989 $8.47 $609,746.83
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 8

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,139

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
April 28, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 71,989 $3.85 $277,157.65
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 7

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 272,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 27, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 65,634 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · derivative · entry 12

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 899,725

Underlying: Common Shares · 65,634 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
April 27, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 5,335 $0.00 Strike: $3.97 $0.00
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · derivative · entry 11

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,335 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that was fully vested.

Read SEC document
April 27, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 70,969 $8.51 $603,946.19
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 6

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,139

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
April 27, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 65,634 $3.85 $252,690.90
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 5

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 271,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 27, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 5,335 $3.97 $21,179.95
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 4

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,474

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 26, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 34,641 $0.00 Strike: $3.85 $0.00
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · derivative · entry 10

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 965,359

Underlying: Common Shares · 34,641 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Read SEC document
April 26, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionStock Option (Right to Buy) · Derivative 53,189 $0.00 Strike: $3.97 $0.00
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · derivative · entry 9

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,335

Underlying: Common Shares · 53,189 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares that was fully vested.

Read SEC document
April 26, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 SaleCommon Shares 87,830 $8.68 $762,364.40
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,139

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Read SEC document
April 26, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 34,641 $3.85 $133,367.85
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 287,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 26, 2023 Filed Apr 29, 2023 01:35 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Exercise / conversionCommon Shares 53,189 $3.97 $211,160.33
Disclosure

SEC source: 0001140361-23-021749 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 253,328

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 20, 2023 Filed Apr 25, 2023 01:28 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantStock Option (Right to Buy) · Derivative 286,408 $0.00 Strike: $8.80 $0.00
Disclosure

SEC source: 0001140361-23-019992 · form4.xml · derivative · entry 3

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,408

Underlying: Common Shares · 286,408 shares

Expires 2033-04-19

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2023. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Read SEC document
April 20, 2023 Filed Apr 25, 2023 01:28 UTC Roivant Sciences Ltd. ROIV · Entity 3185 Tax withholdingCommon Shares 1,569 $8.80 $13,807.20
Disclosure

SEC source: 0001140361-23-019992 · form4.xml · nonDerivative · entry 2

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,139

F3 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
April 20, 2023 Filed Apr 25, 2023 01:28 UTC Roivant Sciences Ltd. ROIV · Entity 3185 GrantCommon Shares 66,710 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-019992 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,708

F1 · shares: Reflects an award of 66,710 restricted stock units with respect to Common Shares ("RSUs") with a vesting commencement date of April 20, 2023. 1/4 of the RSUs service-vest twelve (12) months after the vesting commencement date; 1/16 of the RSUs service-vest fourteen (14) months after the vesting commencement date; and the balance of the RSUs service-vest in a series of eleven (11) successive equal quarterly installments measured from the date fourteen (14) months after the vesting commencement date, subject to the reporting person's Continuous Service through the applicable vesting date.

F2 · balance_after: Includes Common Shares purchased under the Company's Employee Stock Purchase Plan.

Read SEC document
March 23, 2023 Filed Mar 28, 2023 01:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 2,134 $7.30 $15,578.20
Disclosure

SEC source: 0001140361-23-014075 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,409

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
February 22, 2023 Filed Feb 25, 2023 02:30 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,797 $8.43 $15,148.71
Disclosure

SEC source: 0001140361-23-008668 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,543

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document
January 24, 2023 Filed Jan 27, 2023 02:01 UTC Roivant Sciences Ltd. ROIV · Entity 3185 OtherCommon Shares 1,838 $8.56 $15,733.28
Disclosure

SEC source: 0001140361-23-002959 · form4.xml · nonDerivative · entry 1

Kumar Rakhi · CIK 0001856296 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,340

F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.